πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

Showing page 857 of 857 Β· Phase 3 first, then by program name

  1. zoledronate therapy

    United Therapeutics Europe Ltd

    Prostate Cancer

    small molecule completed

    1 trial
  2. zuojinwan

    The First People's Hospital of Lianyungang

    Functional Dyspepsia

    small molecule active

    1 trial
  3. Ξ²-hydroxy Ξ²-methylbutyrate (HMB) supplement

    Chinese University of Hong Kong

    Sarcopenia

    other active

    1 trial
  4. Ξ³-globin reactivated autologous hematopoietic stem cells

    The First People's Hospital of Lianyungang

    Thalassemia Major

    mab on hold

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources